Cue Biopharma, Inc. (CUE) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 21.22M USD | Liabilities, Current |
| Cash and equivalents | 17.39M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 5.38M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $21.22M | $17.39M | (m) | $5.38M | (m) | (m) |
| 2026-03-31 | (m) | $7.39M | $16.38M | (m) | $5.35M | (m) | (m) |
| 2025-12-31 | (m) | $13.49M | $27.14M | (m) | $5.55M | (m) | (m) |
| 2025-09-30 | $19.06M | $15.52M | $11.70M | $6.97M | $387.00K | (m) | 1.23× |
| 2025-06-30 | (m) | $19.25M | $27.49M | (m) | $532.00K | (m) | (m) |
| 2025-03-31 | (m) | $15.50M | $13.14M | (m) | $0.00 | (m) | (m) |
| 2024-12-31 | (m) | $13.69M | $22.46M | (m) | $945.00K | (m) | (m) |
| 2024-09-30 | (m) | $16.79M | $32.42M | (m) | $3.15M | (m) | (m) |
| 2024-06-30 | (m) | $16.46M | $30.03M | (m) | $1.85M | (m) | (m) |
| 2024-03-31 | (m) | $18.09M | $41.03M | (m) | $1.40M | (m) | (m) |
| 2023-12-31 | $50.21M | $17.08M | $48.51M | $0.00 | $1.70M | (m) | 2.94× |
| 2023-09-30 | $56.35M | $17.21M | $54.69M | $0.00 | $1.66M | (m) | 3.27× |
| 2023-06-30 | $59.02M | $16.31M | $52.90M | $4.99M | $1.14M | (m) | 3.62× |
| 2023-03-31 | $66.39M | $13.81M | $56.32M | $9.88M | $196.00K | (m) | 4.81× |
| 2022-12-31 | $76.35M | $11.55M | $51.61M | $24.67M | $57.25K | (m) | 6.61× |
| 2022-09-30 | $59.98M | $10.22M | $29.73M | $29.46M | $796.00K | (m) | 5.87× |
| 2022-06-30 | $66.86M | $8.32M | $66.13M | $0.00 | $736.00K | (m) | 8.03× |
| 2022-03-31 | $68.85M | $11.41M | $67.93M | $0.00 | $925.00K | (m) | 6.03× |
| 2021-12-31 | $67.51M | $12.79M | $64.37M | $0.00 | $3.14M | (m) | 5.28× |
| 2021-09-30 | (m) | $15.36M | $67.63M | (m) | $771.00K | (m) | (m) |
| 2021-06-30 | (m) | $16.67M | $73.92M | (m) | $1.90M | (m) | (m) |
| 2021-03-31 | (m) | $16.63M | $73.26M | (m) | $1.41M | (m) | (m) |
| 2020-12-31 | $86.29M | $16.32M | $74.87M | $10.00M | $1.42M | (m) | 5.29× |
| 2020-09-30 | $92.26M | $14.23M | $71.73M | $20.07M | $457.00K | (m) | 6.48× |
| 2020-06-30 | $86.16M | $14.86M | $59.75M | $25.18M | $1.23M | (m) | 5.80× |
| 2020-03-31 | $49.34M | $12.09M | $23.43M | $25.30M | $605.00K | (m) | 4.08× |
| 2019-12-31 | $60.16M | $11.66M | $44.29M | $15.12M | $754.90K | (m) | 5.16× |
| 2019-09-30 | $31.99M | $10.39M | $31.38M | $0.00 | $610.00K | (m) | 3.08× |
| 2019-06-30 | $28.78M | $11.27M | $24.26M | $4.00M | $522.00K | (m) | 2.55× |
| 2019-03-31 | (m) | $10.57M | $21.91M | $8.97M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $6.22M | (m) | $18.41M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $4.58M | $15.84M | $23.34M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $2.96M | $45.74M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $53.10M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $63.53M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | $3.40M | $0.00 | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $7.31M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | $10.91M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $14.93M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |